Keyword: Moderna Therapeutics
After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.
An investment fund formed by J.P. Morgan and the Gates Foundation, Global Health Investment Fund led Themis' €10 million series C.
Secretive Moderna shared a new peek into its infectious disease vaccines efforts Thursday.
Moderna has snagged a former Novartis manufacturing exec to oversee completion and scale-up of a $110 million manufacturing facility near Boston.
Merck & Co. may not be number one with a bullet in vaccines, but CEO Ken Frazier says the unit shouldn't be underestimated.
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to make a quick buck.
The highly valued yet mysterious Moderna provided a peek at its first human data, reporting positive interim results from a phase 1 trial testing its mRNA-based H10N8 flu vaccine.
The sun has set on the J.P. Morgan Healthcare Conference, but we're still digesting the multicourse meal of news and commentary. Here's our menu.